Reuters logo
4 个月前
BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN
2017年3月23日 / 上午11点04分 / 4 个月前

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

1 分钟阅读

March 23 (Reuters) - Stemline Therapeutics Inc:

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn

* Stemline Therapeutics Inc - company also reviewed key milestones for sl-401 program over coming year

* Stemline Therapeutics Inc - stemline plans to provide a clinical update on patients enrolled in stages 1 and 2 at a medical conference around mid-year

* Stemline Therapeutics Inc - plans to provide top-line data from stage 3 expected in second half of 2017

* Stemline Therapeutics Inc - plans to continue to enroll both first-line and relapsed/refractory bpdcn patients under current protocol Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below